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Background: Thiazolidinediones are antidiabetic agents that increase insulin sensitivity but reduce glucose
oxidation, state 3 respiration, and activity of complex I of the mitochondrial respiratory chain (MRC). The
mechanisms of the latter effects are unclear. The aim of this study was to determine the mechanisms by which
pioglitazone (PGZ), a member of the thiazolidinedione class of antidiabetic agents, decreases the activity of the
MRC. In isolated mitochondria from mouse liver, we measured the effects of PGZ treatment on MRC complex activities,
fully-assembled complex I and its subunits, gene expression of complex I and III subunits, and [3H]PGZ binding to
mitochondrial complexes.
Results: In vitro, PGZ decreased activity of complexes I and III of the MRC, but in vivo only complex I activity was
decreased in mice treated for 12 weeks with 10 mg/kg/day of PGZ. In vitro treatment of isolated liver mitochondria
with PGZ disassembled complex I, resulting in the formation of several subcomplexes. In mice treated with PGZ,
fully assembled complex I was increased and two additional subcomplexes were found. Formation of
supercomplexes CI+CIII2+CIVn and CI+CIII2 decreased in mouse liver mitochondria exposed to PGZ, while
formation of these supercomplexes was increased in mice treated with PGZ. Two-dimensional analysis of complex
I using blue native/sodium dodecyl sulfate polyacrylamide gel electrophoresis (BN/SDS-PAGE) showed that in vitro
PGZ induced the formation of four subcomplexes of 600 (B), 400 (C), 350 (D), and 250 (E) kDa, respectively.
Subcomplexes B and C had NADH:dehydrogenase activity, while subcomplexes C and D contained subunits of
complex I membrane arm. Autoradiography and coimmunoprecipitation assays showed [3H]PGZ binding to
subunits NDUFA9, NDUFB6, and NDUFA6. Treatment with PGZ increased mitochondrial gene transcription in mice
liver and HepG2 cells. In these cells, PGZ decreased intracellular ATP content and enhanced gene expression of
specific protein 1 and peroxisome-proliferator activated receptor (PPAR)γ coactivator 1α (PGC-1α).
Conclusions: PGZ binds complex I subunits, which induces disassembly of this complex, reduces its activity,
depletes cellular ATP, and, in mice and HepG2 cells, upregulates nuclear DNA-encoded gene expression of
complex I and III subunits.
Keywords: ATP, Mitochondrial respiratory chain, Pioglitazone, Proteomic, Thiazolidinediones* Correspondence: inmagr86@hotmail.com
1Research Center, Laboratory of Gastroenterology and Hepatology, University
Hospital ‘12 de Octubre’, Complutense University, Madrid 28041, Spain
2Centro de Investigación Hospital Universitario ‘12 de Octubre’, Avenida de
Córdoba S/N, Madrid, 28041, Spain
Full list of author information is available at the end of the article
© 2013 García-Ruiz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
García-Ruiz et al. BMC Biology 2013, 11:88 Page 2 of 15
http://www.biomedcentral.com/1741-7007/11/88Background
Pioglitazone (PGZ), a member of the thiazolidinedione
(TZD) class of antidiabetic agents and agonist of the
peroxisome proliferator-activated receptor γ (PPARγ) [1],
improves insulin sensitivity both in the liver and peripheral
tissues. The mechanisms of this effect are unclear. However,
they are attributed to the actions of TZDs on PPARγ [2].
After activating PPARγ receptors, TZDs induce adipocyte
differentiation and remodeling of adipose tissue in vitro
and in vivo [2,3]. It is believed that signals derived from
the adipose tissue (fatty acids, adiponectin, resistin, leptin)
may mediate the improvement in skeletal glucose disposal
induced by TZDs [2,3]. However, it is also likely that other
mechanisms independent of PPARγ may contribute to
TZD effects on insulin sensitivity [4]. Thus, in vitro studies
have shown that TZDs elevate lactate production by skel-
etal muscle [5], suggesting an inhibition of cell respiration
[6]. In fact, several authors have found that the activity of
complex I of the mitochondrial respiratory chain (MRC),
state 3 respiration, and glucose oxidation were reduced in
homogenates of skeletal muscle treated with increased
doses of TZDs [7,8]. PPARγ does not seem to be involved
in these effects of TZDs [5], since they inhibited complex
I in sonicated tissue homogenates containing disrupted
mitochondria [7].
Complex I (NADH:ubiquinone oxidoreductase) is the first
and the largest of the four multiprotein complexes that
constitute the MRC involved in oxidative phosphorylation
[9]. This complex is formed by at least 44 subunits, 7 of
which are encoded by the mitochondrial genome and
the remaining 37 by the nuclear genome [10]. The crystal
structure of the entire Thermus thermophilus complex I
has been recently reported [11]. In previous studies, we
have shown that PGZ suppressed the activity of complex I
of the MRC in ob/ob mice, but the mechanisms of this
effect are still unclear [12].
The aim of the present study was to determine the
mechanisms by which PGZ decreases MRC activity.
We show that PGZ binds subunits located in the mem-
brane arm of complex I of the MRC, which induces
disassembly of this complex, reduces its enzymatic ac-
tivity, depletes cellular ATP, and consequently upregulates
nuclear DNA-encoded gene expression of complex I
subunits.
Results
PGZ decreased activity of complexes I and III of the MRC
in isolated mouse liver mitochondria
As the MRC plays a critical role in the conversion of
NADH and FADH2 into NAD and FAD, respectively,
and in the generation of ATP from ADP [13], we measured
the in vitro effect of increasing concentrations (0 to 15
μM) of PGZ on the activity of MRC complexes isolated
from mouse liver. The activity of complex I, which acceptselectrons from NADH and transfers them to ubiquinone,
decreased in a dose-dependent manner from 55.67 ±
3.7 nmol/min/mg protein in untreated mitochondria
(100%) to 21.98 ± 4.3 nmol/min/mg protein (39.5 ± 0.5%)
in mitochondria treated with 15 μM PGZ for 30 minutes
(Figure 1A). To correct for mitochondrial volume, all
respiratory chain enzyme activities were normalized to
the activity of citrate synthase (CS).
The activity of complex II (succinate dehydrogenase
complex), which passes electrons directly to ubiquinone,
was not affected significantly by PGZ treatment (control,
68.96 ± 4.8 nmol/min/mg protein; 15 μM PGZ, 67.96 ±
5.3 nmol/min/mg protein) (Figure 1A).
Ubiquinone passes electrons from complex I and II
to the b-c1 complex (complex III), which transfers
them to cytochrome c. The activity of complex III also
significantly decreased from 85.71 ± 4.6 nmol/min/mg
protein (control) to 64.20 ± 3.7 nmol/min/mg protein
(P <0.001) (15 μM PGZ).
Cytochrome c is involved in carrying electrons from
the b-c1 complex to the cytochrome oxidase complex
(complex IV), which finally transfers these electrons to
oxygen. Measurement of the activity of this complex in
liver mitochondria exposed to increasing concentrations
of PGZ revealed that this drug did not affect complex IV
activity (controls, 47.21 ± 6.1 nmol/min/mg protein; 15 μM
PGZ, 45.61 ± 5.7 nmol/min/mg protein; not significant
(NS)) (Figure 1A).
ATP synthase or complex V of the oxidative phosphoryl-
ation pathway converts ADP into ATP when protons flow
back from the intermembrane space into the mitochondrial
matrix. The activity of this complex was not significantly
affected by treatment with PGZ (controls, 223 ±
38.6 nmol/min/mg protein; 15 μM PGZ, 215.7 ±
33.1 nmol/min/mg protein; NS) (Figure 1A).Treatment of mice with PGZ decreased activity of complex
I of the MRC
We also studied the effects of PGZ on the activity of
MRC complexes in C57BL/6J mice. In these animals,
treatment with 10 mg PGZ/kg/day for 12 weeks signifi-
cantly decreased the activity of complex I (Figure 1B)
from 52.28 ± 7.16 nmol/min/mg protein in control ani-
mals to 29.32 ± 4.62 nmol/min/mg protein in PGZ-
treated mice (P <0.001), but not the activity of com-
plexes II (control, 50.81 ± 6.74 nmol/min/mg protein;
PGZ, 48.23 ± 5.33 nmol/min/mg protein; NS), III (control,
72.70 ± 8.3 nmol/min/mg protein; PGZ, 73.92 ± 6.28
nmol/min/mg protein; NS), IV (control, 56.13 ± 6.81
nmol/min/mg protein; PGZ, 53.53 ± 7.11 nmol/min/mg
protein; NS), and V (274.46 ± 36.27 nmol/min/mg pro-
tein; PGZ, 275.17 ± 31.63 nmol/min/mg protein; NS)
(Figure 1B).
Figure 1 Pioglitazone (PGZ) decreased enzymatic activity of complex I and III of the mitochondrial respiratory chain. (A) The in vitro
enzymatic activity of mitochondrial respiratory chain (MRC) complexes was measured by spectrophotometry (as described in the Methods
section) in isolated mouse liver mitochondria exposed to 0 to 15 μM PGZ for 30 minutes. Activities were expressed as nM of substrate used per
minute per mg protein and referred to as the percentage of the specific activity of citrate synthase (CS) to correct for the hepatic content in
mitochondria. NS, not significant. **, P <0.001; ***, P <0.001 vs control activity. (B) Effects of PGZ on the enzymatic activity of the MRC and
complex V of the oxidative phosphorylation in mice treated with PGZ for 12 weeks. Ten C57BL/6J mice were treated with 10 mg/kg/day PGZ for
12 weeks. The enzymatic activity of MRC complexes was measured as indicated in the Methods section and expressed as nM of substrate used
per minute per mg protein and, to correct for the hepatic content in mitochondria, referred as a percentage of the specific activity of citrate
synthase (CS). NS, not significant.
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and in vivo
In order to know whether PGZ alters assembly of MRC
complexes, we exposed 30 μg of isolated mitochondria
from normal liver to either 1 or 10 μM PGZ for 0 to 60
minutes. As Figure 2A shows, PGZ decreased the band
corresponding to the fully assembled complex I and
determined the formation of several lower molecular
weight bands (600, 400, 350 kDa) in which the NDUFA9
subunit was also present. These effects were dose and
time dependent. These changes were more evident at
60 minutes of treatment with 10 μM PGZ. As Figure 2B
shows, two of these subcomplexes (600 and 400 kDa)
maintained in-gel enzymatic activity. Treatment of liver
mitochondria with 10 μM PGZ did not affect assembly of
complexes II, III, and IV (Figure 2A).
To determine whether PGZ treatment also alters
assembly of MRC complexes in mice, liver mitochondria
isolated from C57BL/6J mice untreated and treated for 12
weeks with 10 mg/kg/day PGZ via intragastric intubation
were separated using a one-dimensional blue native
polyacrylamide gel electrophoresis (BN-PAGE) systemand analyzed by western blot using antibody against the
complex I subunit NDUFA9, complex II subunit SDHA,
complex III subunit core 2 (UQCRC2), complex IV subunit
COX4, and complex V subunit ATP5A1. As Figure 2C
illustrates, animals treated with PGZ displayed a clear
increase in the fully-assembled complex I as compared to
untreated, control mice. In addition, similar to in vitro
studies, two other subcomplexes of 600 and 400 kDa,
respectively, were detected. The bands corresponding to
the remaining four complexes were not affected by PGZ
treatment. Although fully assembled complex I was in-
creased in PGZ-treated mice, its in-gel activity was clearly
decreased (Figure 2D).
PGZ altered formation of respiratory supercomplexes
To investigate how PGZ affects the formation of respira-
tory supercomplexes, we performed BN-PAGE using the
detergent digitonin instead of n-dodecylmaltoside. This
condition allows loose interaction to remain intact. We
found that complex I was present in the monomeric form
and in two additional supercomplexes also containing
complex III dimer (CI+CIII2) or complex III dimer and
Figure 2 Pioglitazone (PGZ) disassembled complex I of the mitochondrial respiratory chain and altered supercomplex formation.
(A) Mitochondria isolated from a mouse liver were treated with PGZ and analyzed as described in the Methods section. Proteins were separated
using blue native polyacrylamide gel electrophoresis (BN-PAGE). Western blot analysis was performed using antibody against complex I (CI)
subunit NDUFA9, complex II (CII) subunit SDHA, complex III (CIII) subunit core 2, and complex IV (CIV) subunit COX4. SC, subcomplexes.
(B) Mouse mitochondria were incubated with PGZ and proteins were separated by BN-PAGE. Complex I ingel activity was displayed as described
in the Methods section. Lanes: Ctr, control activity; PGZ, isolated mitochondria treated with 10 μM PGZ for 15 or 30 minutes. (C) Mitochondrial
complexes isolated from an untreated mouse and three mice treated with 10 mg/kg/day PGZ for 12 weeks were run under native conditions on
a BN-PAGE system and analyzed by western blot. Lanes: Ctr, control mouse; lane PGZ-1, PGZ-2, PGZ-3, PGZ-treated mice. (D) Mitochondrial
complexes isolated as indicated in (C) were subjected to a complex I in-gel enzyme activity assay as described in Figure 2B. (E) Mouse liver
mitochondria were solubilized in 4 g/g protein digitonin and complexes and supercomplexes were separated by BN-PAGE. Complexes and
supercomplexes were identified by western blot using specific antibodies against subunits NDUFA9, SDHA, core 2, and COX1. CI+CIII2+CIVn,
supercomplex formed by complex I, complex III dimer, and complex IV. CI+CIII2, supercomplex formed by complex I and complex III dimer. C,
untreated mitochondria; P, PGZ-treated mitochondria. (F) Liver mitochondria isolated from PGZ-treated (P) and untreated (C) mice were
solubilized in digitonin and complexes and supercomplexes were separated on a BN-PAGE gel. Complexes and supercomplexes were identified
by western blot using antibodies described in (E). These results are representative of three controls and three PGZ-treated mice.
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chondria with 10 μM PGZ led to a marked decrease in
the monomeric complex I and in both supercomplexes
CI+CIII2 and CI+CIII2+CIVn. This decrease in super-
complex formation was due to a reduced accumulation
of complexes I, III, and IV (Figure 2E). Moreover, forma-
tion of supercomplex CIII+CIV was increased after PGZ
treatment.
Compared to untreated mice, in liver mitochondria
isolated from mice treated with 10 mg/kg/day PGZ
for 12 weeks, we found that monomeric complex I was
unchanged and supercomplexes CI+CIII2+CIVn and CI
+CIII2 were markedly increased. Likewise, supercomplex
CIII+CIV was also augmented (Figure 2F).
PGZ disassembled the membrane arm of complex I
With the intention of characterize subcomplexes formed
after in vitro treatment of isolated mitochondria with10 μM PGZ, we analyzed the presence of representative
subunits of intermediates in the assembly process following
the model proposed by Mimaki et al. [9]. Thus, after PGZ
treatment, MRC complexes were separated as previously
described using first-dimension BN-PAGE, blotted, and
analyzed by western blot using antibodies against subunits
of complex I NDUFA9, NDUFA6, NDUFV1, NDUFV2,
NDUFS1, NDUFS3, NDUFS7, NDUFB6, NDUFB8,
NDUFC2, MTND4, and MTND6. As Figure 3A shows, in
addition to the 980 kDa fully assembled complex I, we
found subunits NDUFV1, NDUFV2, NDUFS1, NDUFA9,
NDUFS3, NDUFS7, MTND6, NDUFB6, NDUFB8, and
NDUFA6 in an approximately 600 kDa molecular weight
subcomplex B. Likewise, subunits NDUFV1, NDUFV2,
NDUFS1, NDUFA9, NDUFS3, NDUFS7, and NDUFA6,
but not MTND6, NDUFB6, and NDUFB8, were found
in a 400 kDa subcomplex C. In an approximately 350
kDa subcomplex D, subunits MTND6, NDUFB6, and
Figure 3 (See legend on next page.)
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Figure 3 Pioglitazone (PGZ) disassembled complex I into four subcomplexes of approximately 600, 400, 350, and 250 kDa,
respectively. (A) Mitochondrial complexes were treated with 10 μM PGZ as described in Methods and Figure 2A, separated on one-dimensional
5% to 15% blue native polyacrylamide gel electrophoresis (BN-PAGE), and analyzed by western blot using antibodies against subunits NDUFA9,
NDUFA6, NDUFV1, NDUFV2, NDUFS1, NDUFS7, NDUFS3, NDUFB6, NDUFB8, NDUFC2, MTND4, and MTND6. Molecular weight was determined by
the mobility of fully assembled complex I (980 kDa), complex V (650 kDa), complex III (500 kDa), complex IV (200 kDa), and complex II (130 kDa).
(B) Mouse liver mitochondria (30 μg) were exposed to 10 μM PGZ for 30 minutes and separated in the first dimension using a 5% to 15%
BN-PAGE gel and in the second dimension using sodium dodecyl sulfate (SDS)-PAGE. Subunits were identified by western blot using specific
antibodies against subunits NDUFA9, NDUFA6, NDUFV1, NDUFV2, NDUFS1, NDUFS7, NDUFS3, NDUFB6, NDUFB8, NDUFC2, MTND6, and MTND4 of
complex I, as well as antibodies against subunits SDHA of complex II, core 2 of complex III, COX4 of complex IV, and subunit ATP5A1 of complex
V. These results are representative of three separate experiments.
García-Ruiz et al. BMC Biology 2013, 11:88 Page 6 of 15
http://www.biomedcentral.com/1741-7007/11/88NDUFB8 were present, all of them belonging to the
membrane arm of complex I. Finally, subunits NDUFC2
and MTND4 were found in an approximately 250 kDa
subcomplex E.
Two-dimensional analysis of complex I confirmed
that treatment of liver mitochondria with 10 μM PGZ
for 30 minutes disassembled complex I as indicated by
the presence of its subunits in the mature fully assembled
complex (Figure 3B, subcomplex A) and four additional
subcomplexes of about 600, 400, 350, and 250 kDa,
respectively (Figure 3B, subcomplexes B, C, D, and E).
Subcomplex B contained subunits NDUFV1, NDUFV2,
and NDUFS1 that are part of the NADH:dehydrogenase
module, NDUFB6, NDUFB8, and MTND6, belonging to
the membrane arm of the complex, and subunits NDUFA9,
NDUFA6, NDUFS3, and NDUFS7 forming part of the
hydrogenase module of complex I. Subunits NDUFV1,
NDUFV2, and NDUFS1 and subunits NDUFA9, NDUFA6,
NDUFS3, and NDNFS7 belonging to the hydrogenase
module were present in subcomplex C. The subcomplex
D of about 350 kDa contained at least subunits MTND6,
NDUFB6, and NDUFB8, all of them forming part of the
membrane arm. Finally, subcomplex E contained at least
subunits NDUFC2 and MTND4, also members of the
membrane arm.
Examination of representative subunits of complexes
II (SDHA), III (UQCRC2 = core 2), IV (COX4), and V
(ATP5A1) showed that only subunit core 2 was modified
by treatment with PGZ (Figure 3B). Thus, this subunit
appeared distributed in one additional subcomplex of
about 300 kDa.
PGZ decreased prohibitin and assembly factors NDUFAF1
(CIA30), and FOXRED1 in mouse liver mitochondria
Because it is known that a number of proteins are
involved in maintaining the stability of complex I, we
investigated whether in vitro isolated mitochondria treat-
ment with 10 μM PGZ for 30 minutes affected mitochon-
drial prohibitin, NDUFAF1 (CIA30), or FOXRED1, three
proteins involved in the assembly/stability of complex I. As
Figure 4 shows, the amount of prohibitin clearly decreased
in mitochondrial protein exposed to PGZ (Figure 4A).
Similarly, for NDUFAF1 (which appeared distributed intwo separated bands of about 700 kDa and 500 kDa,
respectively, in untreated proteins), we found that after
PGZ treatment these two signals were less intense and
a third band of about 600 kDa appeared between them
(Figure 4A). Finally, FOXRED1, that originated a signal
at 500 kDa of molecular weight in untreated proteins,
was not recognized in PGZ-treated proteins (Figure 4A).
Likewise, second-dimension analysis of NDUFAF1 and
FOXRED1 proteins via sodium dodecyl sulfate (SDS)-
PAGE confirmed these effects of PGZ. Thus, after PGZ
treatment, the signal for FOXRED1 disappeared com-
pletely, and NDUFAF1 was distributed in three spots
(Figure 4B).
[3H]PGZ binds to complex I subunits NDUFA9, NDUFB6,
and NDUFA6
To investigate whether PGZ interacts with complex I
or with any of its subunits, we exposed isolated liver
mitochondria to 10 μM [3H]PGZ for 30 minutes. As
shown in Figure 4C, [3H]PGZ binds to mitochondrial
proteins of about 980, 600, and 400 kDa molecular
weight. To identify subunits that PGZ was bound to, we
treated isolated mitochondria with 10 μM [3H]PGZ and
complex I subunits were separated in parallel on two
SDS/BN-PAGE gels as indicated in Methods. Autoradi-
ography showed that [3H]PGZ was bound particularly
to a subunit of 39 kDa, but also to subunits of 17 and
15 kDa that overlapped the signals originated by NDUFA9,
NDUFB6, and NDUFA6, respectively (Figure 4D). The
binding of [3H]PGZ to these subunits was confirmed by
immunoprecipitating mitochondrial subunits after treating
isolated mitochondria with 10 μM [3H]PGZ for 30 minutes
(Figure 4E,F).
Treatment with PGZ increased mitochondrial gene
transcription in mice liver and HepG2 cells
Because fully assembled complex I was increased in mice
treated with PGZ for 12 weeks, we examined the steady-
state levels of nuclear DNA (nDNA)-encoded (NDUFA9,
NDUFB6, NDUFS3, core 2) mRNA and mitochondrial
DNA (mtDNA)-encoded (ND1, ND2, ND4, ND4L) mRNA
in the liver from ten control mice and in ten mice treated
with 10 mg PGZ/kg/day for 12 weeks. This experiment
Figure 4 Pioglitazone (PGZ) decreased the amount of prohibitin, NDUFAF1, and FOXRED1 associated with mitochondrial complexes
and joined subunits NDUFA9, NDUFB6, and NDUFA6 of complex I. Mouse mitochondria were treated with PGZ, proteins were separated by
either blue native polyacrylamide gel electrophoresis (BN-PAGE) (A) or sodium dodecyl sulfate (SDS)/BN-PAGE (B) and analyzed by western blot
using antibodies against prohibitin, NDUFAF1, or FOXRED1. C, control, untreated proteins. P, PGZ treated proteins. (C) Mouse liver mitochondria
were treated with 10 μM [3H]PGZ for 30 minutes. Mitochondrial complexes were separated in parallel on three one-dimensional BN-PAGE gels.
One gel was used to localize [3H]PGZ by autoradiography, the second gel was utilized to analyze complex I by western blot, and the third was
employed to determine complex I in-gel activity. (D) Mitochondrial complexes were separated in parallel on two SDS/BN-PAGE gels. One gel was
analyzed by western blot using antibodies against complex I subunits NDUFS1, NDUFV1, NDUFA9, NDUFV2, NDUFB6, NDUFA6, and NDUFA2. The
second gel was used to localize [3H]PGZ by autoradiography. (E) Liver mitochondria treated with 10 μM [3H]PGZ for 30 minutes were
immunoprecipitated with monoclonal antibody against NDUFA9 (A9), NDUFB6 (B6), NDUFA6 (A6), NDUFV2 (V2), NDUFS1 (S1), core 1 (Cor), and
COX1 (COX) as described in the Methods section. Radioactivity was quantitated in the immunoprecipitates. (F) Mitochondrial proteins treated
with 10 μM [3H]PGZ for 30 minutes were immunoprecipitated as indicated in (E), electrophoresed in a 10% acrylamide gel, and transferred to a
nitrocellulose membrane. Subunits were analyzed by western blot to show specific immunoprecipitation of subunits. Individual bands were
excised and their radioactivity was measured. Lane 1, western blot of not immunoprecipitated mitochondrial proteins. Lanes A6, B6, V2, A9, Cor,
COX, and S1 western blot of immunoprecipitated NDUFA6, NDUFB6, NDUFV2, NDUFA9, core 1, COX1, and NDUFS1 subunits, respectively.
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encoded by the nDNA was increased by 30% to 50% over
control levels in PGZ-treated mice (Figure 5A), whereas ex-
pression of mtDNA encoded complex I subunits remained
at the control levels in PGZ-treated mice. Gene expression
of complex III subunit core 2 was also significantly
increased in these mice.
To ensure that PGZ increases gene expression of MRC
subunits, we treated HepG2 cells with 10 μM PGZ for
5 days and measured expression of complex I subunits
NDUFA9, NDUFB6, NDUFS3, complex III subunits
UQCRC1, UQCRC2, and UQCRFS1, complex IV subunit
COX4, and complex II subunit SDHA. As Figure 5B shows,
treatment of cells with PGZ increased gene expression
of complex I subunits by 30% and complex III by 20% to
30%, but did not increase significantly gene expression
of complex II and IV subunits.
PGZ reduced intracellular ATP content and upregulated
gene expression of specific protein 1 (Sp1) and PPARγ
coactivator 1α (PGC-1α) in HepG2 cells
To determine whether PGZ modifies intracellular ATP
content, HepG2 cells were cultured in the absence orpresence of 10 μM PGZ for 5 days. As Figure 5C shows,
treatment of cells with 10 μM PGZ decreased cellular
ATP from 10.93 ± 0.85 nmol/mg protein to 4.18 ± 0.42
nmol/mg protein (P <0.0001). To examine whether PGZ
modifies gene expression of transcription factors involved
in the regulation of gene encoding MRC proteins, we
exposed HepG2 cells to 10 μM PGZ for 5 days and
measured gene expression of Sp1, estrogen related receptor
α (ERRα), and PGC-1α of the MRC by real-time polymerase
chain reaction (RT-PCR). We found that PGZ treatment
increased significantly gene expression of Sp1 and PGC-1α,
but not of ERRα (Figure 5D).
Discussion
Our results shows that in vitro PGZ significantly inhibits
complex I activity and, less intensely but also significantly,
complex III in isolated liver mitochondria. Likewise, treat-
ment of mice with PGZ for 12 weeks at a dose that
has demonstrated to have pharmacologic effects (10 mg
PGZ/g/day) [14] resulted in a significant decrease in
complex I, but not complex III, activity. These results are
consistent with those obtained by others with PGZ and
other TZDs [7,8,15] and with those we have previously
Figure 5 Pioglitazone (PGZ) upregulated mitochondrial respiratory chain (MRC) subunit gene expression in C57BL/6J mice and HepG2
cells. (A) Gene expression of representative subunits of complex I (MTND1, MTND2, MTND4, MTND4L, NDUFA9, NDUFS3, NDUFB6), complex II
(SDHA), complex III (UQCRC1, UQCRC2, UQCRF1), complex IV (COX4) subunits, and β-actin was measured by quantitative real-time polymerase
chain reaction (RT-PCR) in the liver from ten PGZ-treated and ten untreated C57BL/6J mice. The subunit mRNA/β-actin mRNA ratio was
calculated. Data are expressed as fold change over control mice. NS, not significant. (B) Gene expression of subunits of complex I (NDUFA9,
NDUFS3, NDUFB6), II (SDHA), III (UQCRC1, UQCRC2, UQCRF1), and IV (COX4) was measured in HepG2 cells treated with 10 μM PGZ for 5 days.
Messenger RNA (mRNA) of subunits was analyzed by RT-PCR following the procedure described in the Methods section. The subunit/β-actin
mRNA ratio was calculated. Data are expressed as fold change over control cells. NS, not significant. (C) ATP content in HepG2 cells treated with
10 μM PGZ for 5 days. Data are representative of one experiment that was repeated by quintuplicate four times with similar results. (D,E) Effects
of PGZ on estrogen-related receptor α (ERRα), specific protein 1 (Sp1) and peroxisome-proliferator activated receptor (PPAR)γ coactivator 1α (PGC-1α)
gene expression in HepG2 cells and mice. (D) HepG2 cells were treated with 10 μM PGZ for 5 days. Messenger RNAs of ERRα, Sp1, and PGC1α
were analyzed by RT-PCR following the procedure described in the Methods section. The subunit/β-actin mRNA ratio was calculated. Data are
expressed as fold change over control cells. NS, not significant. (E) ERRα, Sp1, and PGC1α gene expression was analyzed by RT-PCR in the liver of
mice treated with 10 mg/kg/day PGZ for 12 weeks. NS, not significant.
García-Ruiz et al. BMC Biology 2013, 11:88 Page 8 of 15
http://www.biomedcentral.com/1741-7007/11/88reported in ob/ob mice [12]. Although some authors
found that this effect of PGZ on complex I activity was
not dose-dependent [15], we found a clear relationship
between the dose of PGZ and the decrease in complex
activity (Figure 1A). In contrast, we found no effects of
PGZ on complex II, IV, or V activity.
Mechanisms by which PGZ decreases complex I and
III activity are not well understood. Complex I transfers
two electrons from NADH to ubiquinone, represents the
main entrance site for electrons into the MRC, and
translocates four protons across the mitochondrial inner
membrane [16]. It is composed of two arms formingan L-shaped structure. One arm is hydrophobic and is
embedded in the inner mitochondrial membrane, whereas
the other arm is hydrophilic and protrudes into the
mitochondrial matrix. While the hydrophilic arm is formed
by subunits involved in electron transfer from NADH to
ubiquinone, the membrane arm is responsible for the
proton translocation [17].
Activity of complex I can be reduced as a result of a
large number of factors including mutations in complex
I subunits [18], physiological molecules, such as nitric
oxide [19], drugs, such as rotenone and TZD [7,15,20], or
oxygen or nitrogen derived reactive substances such as
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stability of this complex may also result in a reduced activity
of complex I.
Our study shows that PGZ affects the stability of complex
I as indicated by the presence of its subunits in the mature
holoenzyme and four additional lower molecular weight
subcomplexes with apparent molecular masses of 600,
400, 350, and 250 kDa, respectively. The assembly process
of complex I is still not completely understood and a
number of different assembly models have been proposed
[9]. However, in our study, the presence of these four
additional subcomplexes cannot be attributed to an effect
of PGZ on the assembly process, in as much as we added
the PGZ to mitochondria isolated from the liver of a
normal mouse in which complexes are fully assembled as
shown in control untreated proteins. Therefore, formation
of these four subcomplexes may be the result of the
fragmentation of complex I into subcomplexes. The sub-
complex B of approximately 600 kDa of molecular weight
has NADH:dehydrogenase activity (Figure 2B) and contains
the same subunits as the mature holoenzyme A, except
subunits NADUFC2 and MTND4 (Figure 3A,B), which
appear in the small subcomplex E of about 250 kDa.
Following the assembly model proposed by Mimaki et al.
[9], these subunits are components of a subcomplex
also containing subunit MTND5 that bind to the distal
end of the membrane arm of complex I (Figure 6). Thus,
subcomplexes B and E may be the result of the detachment
of this distal end of the mature complex I. The subcomplex
D, of about 350 kDa of molecular weight, contains subunits
MTND6, NDUFB6 and NDUFB8 of the membrane arm
of complex I, but not the remaining studied subunits.
Therefore, this subcomplex may also correspond to a
fragment that has been detached from the membrane
arm of subcomplex B (Figure 6). The subcomplex C, of
approximately 400 kDa of molecular weight and with
NADH:dehydrogenase activity (Figure 2B), may be the
remaining fragment of complex I after having lost sub-
complexes E and D (Figure 6).
Mechanisms by which PGZ destabilizes complex I
are unclear. A number of factors have been recognized
to be implicated in the assembly/stabilization of complex
I, including complex III [22], NDUFAF1 (CIA30) [23],
NDUFAF2 (B17.2L) [24], NDUFA9 complex I subunit
[25], FOXRED1 [26], and prohibitin [27], among others.
Although our study shows that in vitro treatment of
isolated mitochondria with PGZ markedly altered these
proteins, we do not believe that the PGZ-induced disas-
sembly of complex I resulted from the effects of PGZ
on these stabilizing proteins, as some of these proteins
(NDUFAF1, NDUFAF2) dissociate before complex I is
completely assembled and are not found in the mature
holoenzyme [23,24]. Prohibitin, a protein that likely
prevents complex degradation by AAA-metalloproteinases[27], decreased in parallel with fully assembled complex
I (Figure 4A). However, our study cannot differentiate
whether PGZ-induced complex I fragmentation was the
result of the reduced amount of prohibitin or, on the
contrary, prohibitin bound to complex I was reduced
because PGZ had decreased fully assembled complex I. In
the case of NDUFAF1, a chaperone not found associated
with mature complex I, PGZ induced its binding to a new
complex of 600 kDa, likely the subcomplex B formed after
fragmentation of complex I. (Figures 4A,B, and 6). The
effect of PGZ on FOXRED1 is difficult to interpret as very
little is known about the function of this protein [26]. We
are not aware of other studies that have been published
on the effects of TZDs on prohibitin or other chaperone
proteins.
Our study also shows the binding of radiolabeled PGZ
to mature complex I and subcomplexes of 600 and 400
kDa of molecular weight (Figure 4C). Little information
is available in the literature concerning the interaction
of TZD with complex I proteins, although it has been
suggested that PPARγ ligands interact directly with this
complex [7]. Only Colca et al. have studied the interaction
of PGZ with mitochondrial membranes and found that
radiolabeled PGZ binds to a 17-kDa mitochondrial protein
[28]. Our study shows the binding of PGZ to complex I
components, particularly to NDUFA9, NDUFB6, and
NDUFA6 subunits (Figure 4). These subunits are hydro-
phobic and are situated in the inner mitochondrial mem-
brane. TZD, like other inhibitors of this complex [29], are
highly lipophilic and bind mitochondrial membrane [30].
Thus, we could speculate that molecular changes induced
by the binding of PGZ to these subunits may destabilize
complex I resulting in the progressive fragmentation of its
membrane arm.
The decrease in complex III activity observed after
in vitro treatment of mitochondria with PGZ may be
ascribed to the fact that complexes I and III interact
physically to form supercomplexes that improves electron
transfer between them [31] and stabilizes complex III [18].
Therefore, PGZ-induced disassembly of complex I may also
indirectly compromise complex III stability and activity. In
accordance with these facts, our study shows that in vitro
addition of PGZ to isolated mitochondria reduced not
only the amount of complex I, but also the formation of
supercomplexes CI+CIII2+CIVn and CI+CIII2 (Figure 2E).
In contrast, supercomplexes CI+CIII2+CIVn and CI+CIII2
were clearly increased in mice treated with PGZ for 12
weeks. This increase in the formation of supercomplexes
in PGZ-treated mice, may justify why complex III activity
remained normal in these animals (Figure 2F). This elevated
accumulation of complex I and III to form supercomplexes
might be a consequence of the association of MRC com-
plexes to form more efficient respiratory structures [32]
that might compensate the reduced activity of complex
Figure 6 Schematic representation of the pioglitazone (PGZ)-induced fragmentation of complex I (A) into four subcomplexes. In the
presence of PGZ, the membranous arm of complex I releases a fragment of 250 kDa (E). As a result of this release, one subcomplex of about 600
kDa (B) is formed. Subsequently, the membrane arm of subcomplex (B) releases a second fragment of 350 kDa (D). Thereafter, the remaining
complex I is limited to a subcomplex of 400 kDa (C). Subcomplexes (B) and (C) contain the NADH:dehydrogenase module and consequently
have in-gel dehydrogenase activity.
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formation may also contribute to the elevated synthesis
of complex I and III subunits.
The present study also shows that treatment of mice
with PGZ for 12 weeks increased the amount of fully
assembled complex I (Figure 2C), although its activity
was significantly decreased (Figures 1B and 2D). Similar to
what occurred in in vitro studies, these in vivo studies
demonstrated the presence of two additional subcomplexes
of 600 kDa and 400 kDa (Figure 2A) indicating that com-
plex I was also disassembled. The increased amount of
fully assembled complex I found in PGZ-treated mice
may be ascribed to the fact that gene expression of nuclear
DNA-encoded complex I subunits was significantly in-
creased (Figure 5A). Our study shows that PGZ increased
gene expression of complex I and, to a lesser extent, com-
plex III subunits in mice and HepG2 cells (Figure 5A,B).
These effects may be interpreted as a compensatory re-
sponse to the decreased activity of these complexes found
after treatment with PGZ. Transcription of MRC subunits
is coordinated with energetic needs of the cells. Thus, the
cellular pool of ATP, the primary end product of oxidative
phosphorylation, plays a key role in the control of nuclear
and mitochondrial transcription [33,34]. In the presentstudy we clearly show that incubation of HepG2 cells
with PGZ significantly decreased cellular content of
ATP (Figure 4C). Therefore, it might be expected that
decreased ATP formation as a result of the PGZ-induced
complex I inhibition might lead to an increased tran-
scription of some components of the MRC. The lack of
increased expression of mtDNA-encoded subunits in
PGZ-treated mice may be attributed to the reduced ability
of cells to repair mtDNA damage [35]. A large number of
transcription factors have been shown to be involved in the
regulation of genes encoding MRC proteins and assembly
factors, including stimulatory protein 1 (Sp1), ERRα, and
transcriptional coactivator PPARγ (PGC1α), among others
[36]. In particular, transcriptional coactivator PGC1α plays
a critical role in adaptation mechanisms to caloric restric-
tion and ATP reduction [37]. In our study, we show that
treatment of mice with PGZ or exposition of HepG2 cells
to PGZ induced the expression of transcription factors Sp1
and particularly PGC1α (Figure 5D,E). Very little informa-
tion is available about the effects of TZD on gene expres-
sion of components of the MRC and its regulatory factors.
Strum et al. found that rosiglitazone increases expression
of genes regulating mitochondrial biogenesis in mice and
that this effect was associated with an increased level of
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Boden et al. found that troglitazone and other TZDs,
upregulated gene expression and synthesis of proteins
involved in electron transport and oxidative phosphor-
ylation in subcutaneous fat [39], and Mensink et al.
demonstrated that rosiglitazone increased PGC1α gene
expression in patients with type 2 diabetes mellitus [40].
Conclusions
In summary, in the present study we show that PGZ
binds complex I subunits, likely NDUFA9, NDUB6, and
NDUFA6, which may induce disassembly of this complex,
reduces its activity, depletes cellular ATP, and, in mice and
HepG2 cells, upregulates nuclear DNA-encoded gene
expression of complex I and III subunits. Elucidation of
the molecular mechanisms by which PGZ binding provokes
disassembly of complex I requires further studies.
Methods
In vitro experiments
The effects of PGZ on the MRC were explored in mito-
chondrial complexes isolated from the liver of C57BL/6J
mouse and from the hepatocellular carcinoma cell line
(HepG2; American Type Culture Collection (ATCC))
cultured in Dulbecco’s modified Eagle medium (Lonza
Iberica SA, Barcelona, Spain) with 10% fetal calf serum, 1%
L-glutamine, 1% penicillin, 1% streptomycin, 1% fungizone.
In vivo experiments
All procedures on mice were carried out in accordance
with the Spanish Guidelines for the Care and Use of
Laboratory Animals. The 6-week-old male C57BL/6J
mice were purchased from Charles River Laboratory
(Charles River Laboratories España SA, Santa Perpetua de
la Mogoda, Spain). Animals were housed at constant
room temperature (23°C) (n = 3 per cage) under 12 h
light/dark cycles with ad libitum access to water and
standard laboratory mouse chow. A total of 20 mice were
distributed into two groups: group I (control) included 10
untreated mice; group II (PGZ) consisted of 10 mice
treated with 10 mg/kg/day of PGZ by daily gavage
(Hartmann Analytic, Grupo Taper SA, Alcobendas, Spain)
for 12 weeks. Food but not water was withdrawn overnight
before mice were killed. The last PGZ dose was admin-
istered 20 h before tissue harvesting. Following the
treatment, animals were anesthetized and killed at
18 weeks of age, and the liver was rapidly harvested for
further analysis.
Extraction of MRC complexes from mouse liver
Mitochondrial isolation from mouse liver samples was car-
ried as described by Schägger et al. [41] with some modifi-
cations. Briefly, liver samples (50 mg; wet weight) were
homogenized in a tightly fitting glass-teflon homogenizerwith about 500 μl of homogenizing buffer, buffer A (440
mM sucrose, 20 mM 3-(N-morpholino)propanesulfonic
acid (MOPS), 1 mM ethylenediaminetetra-acetic acid
(EDTA), pH 7.2, and 0.2 mM phenylmethylsufonyl fluoride).
The sediment was homogenized in 500 μl of buffer B
(500 mM NaCl, 10 mM MOPS, pH 7.2). After centrifuga-
tion at 20,000 g, 150 μl of the 1 M aminocaproic acid, 50
mM Bis-Tris–HCl buffer C (pH 7.0) and 20 μl of Brij 35
detergent solution was added. Mitochondrial pellets from
mouse liver were suspended in an appropriate volume of
buffer D (1 M 6-amiohexanoic acid, 50 mM Bis-Tris/HCl,
pH 7.0), and the membrane proteins were solubilized by
the addition of the indicated detergent and incubated for
10 minutes in ice. After centrifugation for 15 minutes at
100,000 rpm at 4°C, the supernatant was collected, and
one-third of the final volume of the sample of 5% Serva
Blue G dye in 1 M 6-amiohexanoic acid was added prior
to loading. The following detergents were used (a) 3%
(w/v) n-dodecyl β-D-maltoside (DDM) for preparation
of native MRC complexes and (b) 4 g/g protein digitonin
(DIG) to detect the supercomplexes.
MRC activity assays
Frozen liver tissues (50 to 70 mg) were homogenized
with 15 vol. of 20 mmol/L KP buffer (K2HPO4), pH 7.4,
and centrifuged at 800 g for 10 minutes. MRC enzymes
and citrate synthase (CS) activities were measured in a
DU-650 spectrophotometer (Beckman Instruments, Palo
Alto, CA, USA). Incubation temperatures were 30°C for
complexes I, II, III, V and CS, and 38°C for complex IV.
Enzyme activities were performed in supernatants as
described elsewhere [42], expressed as nM of substrate
used per minute per mg protein and, to correct for the
hepatic content of mitochondria, referred as a percentage
of the specific activity of CS. Enzyme assays were performed
in quintuplicate.
Assessment of full assembly of MRC complexes
MRC complexes from were isolated by one-dimensional
BN-PAGE as described elsewhere [21]. Following electro-
phoresis, proteins were transferred to a polyvinyl difluoride
membrane (0.45-μm pore size) (Immobilon-P transfer
membrane; Millipore Co., Bedford, MA, USA). Western
blotting of these proteins was performed using primary
antibodies against complex I subunits NDUFA6, NDUFA9,
NDUFC2, NDUFV1, NDUFV2, NDUFS1, NDUFS7, NDUFS3,
NDUFB6, NDUFB8, MTND6, complex II subunit 70 (SDHA),
complex III subunit core 2 (UQCRC2), complex IV sub-
unit COX-IV (COX4) and complex V subunit α (ATP5A1)
(Molecular Probes Inc., Eugene, OR, USA) on blocking
buffer for 2 h. After washing, blots were incubated for
1 h with peroxidase-conjugated antibody as a second-
ary antibody, prepared at a 1:5,000 dilution (Molecular
Probes Inc.). Immunoreactive material was visualized
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GE Healthcare, Madrid, Spain) according to the manu-
facturer’s instructions. The blot was finally exposed to
Hyperfilm MP (Amersham, GE Healthcare).
Second-dimension electrophoresis for assessing
complex subunits
For second-dimension SDS-PAGE, we followed the pro-
cedure previously described [21]. Following electro-
phoresis, proteins were transferred to a polyvinyl difluoride
membrane. Western blotting was performed using primary
antibodies against complex I subunits NDUFA9, NDUFS3,
NDUFB6 (Molecular Probes Inc.), NDUFV1, NDUFV2,
NDUFS1, NDUFA6, MTND1, MTND2, MTND4, and
MTND4L (Santa Cruz Biotechnology, Inc. Santa Cruz,
CA, USA), complex II subunit SDHA, complex IV subunit
COX4, complex V subunit ATP5A1 (Molecular Probes
Inc.) in blocking buffer for 2 h. After washing, blots were
treated as indicated above.
In-gel activity assays
MRC complexes were separated by one-dimensional BN-
PAGE as described above and complex I in-gel activity
was measured as described by Nijtmans et al. [43].
Quantitative real-time polymerase chain reaction
Total RNA was extracted from cultured HepG2 cells
and from the liver of control and PGZ-treated C57BL/6J
mice using the TRI-Reagent (Sigma-Aldrich, Steinheim,
Germany) according to the manufacturer’s instructions.
RNA was treated with DNase I to remove DNA contam-
ination (Sigma-Aldrich). cDNA was generated from 1 μg
sample RNA using First Strand cDNA Synthesis Kit for
RT-PCR (Roche Applied Science, Indianapolis, IN, USA)
at 25°C, 5 minutes; 42°C, 60 minutes; 95°C, 5 minutes, and
4°C, 5 minutes. Quantitative real-time PCR was performed
on a Light Cycler 1.0 (Roche Applied Science) in 20 μl with
50 ng cDNA, 0.5 μM primers, and 2 μl FastStart DNA
Master SYBR Green I (Roche Applied Science). Data from
the real-time, quantitative PCR were analyzed following
the method described elsewhere [21]. Sequences of primers
used in these experiments are shown in Table 1. Expression
of complex I subunits was normalized to that corre-
sponding β-actin. The amplification conditions were
45 cycles of denaturation at 95°C for 10 s, annealing at
57°C for 5 s, and extension at 72°C for 20 s. The correct
size and purity of the amplified products was verified by
agarose gel electrophoresis.
Western blot analysis
MRC complexes were isolated by BN/SDS-PAGE as
described above and the filters containing proteins
were incubated with appropriated polyclonal antibodies
against prohibitin, FOXRED1, and NDUFAF1 (Santa CruzBiotechnology, Inc. Santa Cruz, CA, USA). Signals were
detected using the ECL Western Blotting Detection
Reagent (Amersham Ibérica, Madrid, Spain).
Measurement of total intracellular ATP content
HepG2 cells were grown to confluence in 75 cm2 tissue
culture flasks (approximately 1.0×106 cells) and detached
using trypsin. After washing in phosphate-buffered saline
(PBS), cell pellets were divided into two portions for
duplicate experiments. Before ATP determination, pellets
were homogenized using perchloric acid and centrifuged
ice cold at 15,000 g for 2 minutes to pellet insoluble
materials. Supernatant was collected and 30 μl was added
to a 96-well plate, then brought up to 50 μl with ATP
assay buffer. ATP reaction mix and ATP measurement
was performed using the ATP Colorimetric/Fluorometric
Assay Kit (BioVision Research Products, Linda Vista, CA,
USA) according to the manufacturer’s protocol.
Binding of [3H]PGZ to complex I subunits
A total of 100 μg of liver mitochondria isolated from a
C57BL/6J mouse were incubated with 10 μM [3H]PGZ
(PGZ 3H(G) hydrochloride; Hartmann Analytic, Grupo
Taper SA, Alcobendas, Spain) at 27°C for 30 minutes.
Afterwards, proteins were separated in parallel, simultan-
eously, on three one-dimensional BN-PAGE as described
above. Following electrophoresis, proteins from one of
these three gels were transferred to a polyvinyl difluoride
membrane (0.45-μm pore size) (Immobilon-P transfer
membrane; Millipore) as previously described [20].
Western blotting of these proteins was performed using pri-
mary antibodies against complex I subunit 39 (NDUFA9),
on blocking buffer for 2 h (Molecular Probes Inc.). The
second gel was used to visualize radioactive subunits by
autoradiography. The third gel was utilized to visualize
complex I in-gel activity. Likewise, subunits of complex
I were separated in parallel, simultaneously, on two
SDS/BN-PAGE gels as described above. Following second-
dimension electrophoresis, subunits from one of these two
gels were transferred to a polyvinyl difluoride membrane
as previously described and identified using antibodies
against subunits NDUFA6, NDUFA9, NDUFB6, NDUFS1,
NDUFV1, NDUFV2, and NDUFA2. The second gel was
used to visualize radioactive subunits by autoradiography.
Coimmunoprecipitation analysis
Liver mitochondria were isolated from liver homogenates
by differential centrifugation as described elsewhere [13].
Mitochondrial pellets were treated with 10 μM [3H]PGZ
for 30 minutes and lysed in radioimmunoprecipitation
assay (RIPA) buffer (20 mM Tris/HCl, pH 7.5; 150 mM
NaCl; 2 mM EDTA; 1% sodium deoxycholate; 1% Triton
X-100; 0.25% SDS). A total of 800 μg of mitochondrial
lysates were incubated with 2 μg monoclonal antibody
Table 1 Primers used in quantitative real-time
polymerase chain reaction
Primer name Direction Sequence
Mouse NDUFA9
(39 kDa)
Sense 5′-CAT TAC TGC AGA GCC ACT-3′
Antisense 5′-ATC AGA CGA AGG TGC ATG AT-3′
Mouse NDUFB6
(17 kDa)
Sense 5′-ATA ACT TTT TGC GGG ACG GG-3′
Antisense 5′-CAG GAA AAT CTC TCA TTG GTG-3′
Mouse NDUFS3
(30 kDa)
Sense 5′-AGG AAC ATG GCG GCG GCT GC-3′
Antisense 5′-ATT TCA GCC ACA TAC TCT CC-3′
Mouse MTND1
(ND1)
Sense 5′-TGC ACC TAC CCT ATC ACT C-3′
Antisense 5′-ATT GTT TGG GCT ACG GCT C-3′
Mouse MTND2
(ND2)
Sense 5′-ATG AGT AGG CCT GGA ATT C-3′
Antisense 5′-ATC AGA AGT GGA ATG GGG C-3′
Mouse MTND4
(ND4)
Sense 5′-ATA ATT ATA ACT AGC TCA ATC TGC-3′
Antisense 5′-TCG TAG TTG GAG TTT GCT AG-3′
Mouse MTND4L
(ND4L)
Sense 5′-CTC ACC ATA GCC TTC TCA C-3′
Antisense 5′-CGT AAT CTG TTC CGT ACG TG-3′
Mouse β-actin Sense 5′-ATG GAT GAC GAT ATC GCT G-3′
Antisense 5′-GTT GGT AAC AAT GCC ATG TTC-3′
Mouse UQCRC1
(core 1)
Sense 5′-CCT ACA GCA CTC GAG AGC AC-3′
Antisense 5′-AGG TGT GCC CTG GAA TGC TG-3′
Mouse UQCRC2
(core 2)
Sense 5′-TCC CTC AAA GTT GCC CC-3′
Antisense 5′-GCA AGA CGT AGT AAA TGT GAG-3′
Mouse UQCRFS1
(FeS)
Sense 5′-GAT GTC AAG GTG CCC GAC TT-3′
Antisense 5′-GAT CTC GAT CTT CGA CAT GG-3′
Mouse SDHA
(70 kDa)
Sense 5′-CAT ACT GTT GCA GCA GCA CAG G-3′
Antisense 5′-CCA CCA AAT GCA CGC TGA TA-3′
Mouse COX4
(COX IV)
Sense 5′-GAG CAC ATG GGA GTG TTG TG-3′
Antisense 5′-CTG TCT TCC ATT CAT TGG TGC C-3′
Mouse PGC1α Sense 5′-GAG ACT TTG GAG GCC AGC AAG-3′
Antisense 5′-CCA AGG GTA GCT CAG TTT ATC AG-3′
Mouse ERRα Sense 5′-GAC AGT CCA AAG GGT TCC TCA G-3′
Antisense 5′-CTG GAT GGT CCT CTT GAA GAA GGC-3′
Mouse SP1 Sense 5′-CTG CCA GCT TGG TGT CAT CAC-3′
Antisense 5′-CTG ACT TCC TTG CAG CGA GC-3′
Human NDUFA9
(39 kDa)
Sense 5′- GAT TGT GGC CAC TGT GTT TGG-3′
Antisense 5′-CTC CAG CTT CCT TGG ACA GT-3′
Human NDUFS3
(30 kDa)
Sense 5′-GTC AGA CCA CGG AAT GAT GTG-3′
Antisense 5′-CTC AAA ACG GTT TTG CCG AG-3′
Human NDUFB6
(17 kDa)
Sense 5′-CTG CAG CAG CTG CGA GA-3′
Antisense 5′-GAA TAA TCC AGA CAG GTA CAA G-3′
Human UQCRC1
(core I)
Sense 5′-GTT AGC CTG CTG GAC AAC G-3′
Antisense 5′-CTT GAT GTA GTA AGC TGT GTG C-3′
Human UQCRC2
(core II)
Sense 5′-CCA AAT GGC TTG GTG ATT GC-3′
Antisense 5′-CAT TAG AAT ATC AAC ATC ACC CC-3′
Human UQCRFS1
(FeS)
Sense 5′-GCC TGT GTT GGA CCT GAA G-3′
Table 1 Primers used in quantitative real-time
polymerase chain reaction (Continued)
Antisense 5′-CTG GAA ACG AAC TGG GTG AC-3′
Human COX4
(COX IV)
Sense 5′-CAG GGT ATT TAG CCT AGT TGG-3′
Antisense 5′-CTC CTT GAA CTT AAT GCG ATA C-3′
Human SDHA
(70 kDa)
Sense 5′-GGC TTG CGA GCT GCA TTT GG-3′
Antisense 5′-GTT CTG CTA AAC GGC ATG CCA-3′
Human PGC1α Sense 5′-GCA AAC TTG CTA GCA GTC CTC-3′
Antisense 5′-GGT ACT GAG CCA ACT GCA TTC-3′
Human ERRα Sense 5′-GAG TGT GAG ATC ACC AAG CG-3′
Antisense 5′-CAC ATG AGA CAC CAG TGC ATT C-3′
Human SP1 Sense 5′-CAG CAG AAT TGA GTC ACC CAA T-3′
Antisense 5′-CAT ACT GCC CAC CAG AGA C-3′
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COX1; core 1) at 4°C overnight. Following incubation, the
immune complexes were precipitated with 50 μl protein
G (NDUFA9, NDUFB6, core 1, COX1) or protein A
(NDUFA6, NDUFS1, NDUFV1) MicroBeads (Miltenyl
Biotec Inc. Auburn, CA, USA) for 4 h on ice. Columns
were placed in the magnetic field of the μMACS separator
and rinsed with 200 μl PBS buffer (pH 7.5). Precipitates
were placed onto the columns and let to run through. The
columns were rinsed four times with 200 μl PBS buffer
and once with 100 μl low salt buffer (20 mM Tris/HCl
(pH 7.5)). Afterwards, 20 μl of preheated 95°C hot 1 × SDS
gel loading buffer (50 mM Tris/HCl (pH 6.8); 50 mM
dithiothreitol; 1% SDS; 0.005% bromophenol blue; 10%
glycerol) was applied to the column and incubated for 5
minutes at room temperature. Following incubation, 50 μl
of preheated 95°C hot SDS gel loading buffer was added
and elute was collected as immunoprecipitate. This
was separated into two aliquots. In one of these, the
radioactivity of the sample was quantitated by scanning
laser densitometry (Desk TopTM Scanner Plus, Amersham
Pharmacia Biotech). The second aliquot was electropho-
resed in a 10% acrylamide gel and transferred to a nitrocel-
lulose membrane. Subunits were analyzed by western blot.
In addition, the individual bands in the blot containing
subunits were excised and their radioactivity was measured
by liquid scintillation spectrophotometry.Statistical analysis
Statistical analysis was performed using SPSS Statistical
Software for Windows, version 9 (SPSS Inc. Chicago,
IL, USA). The unpaired t test was used to assess the
significance of differences between means. Each in vitro
experimental condition was repeated three to four times.
Quantitative data are expressed as the mean ± SD unless
otherwise mentioned. P values <0.05 were considered
significant.
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